Author: [email protected]

Release – Aurania Grants Stock Options Including Options in Lieu of Fees to Directors

Posted on by [email protected]

Toronto, Ontario–(Newsfile Corp. – June 30, 2026) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) announces that its Board of Directors granted 3,260,000 stock options to directors, officers, and employees (the “Optionees”) pursuant to the terms and subject to the conditions of the Company’s Incentive Stock Option Plan.

The 3,260,000 stock options were granted to directors, officers, and employees on June 30, 2026, and have an exercise price of C$0.185. These options are exercisable for five years from the date of grant and the options shall vest in thirds on the date of grant and each of the first and second anniversaries of the dates of grant, always subject to the Optionee’s maintenance of continuous status as an employee, director, or officer of the Company.

In addition to the options noted above, certain Directors of the Company agreed to receive their quarterly director fees for the second quarter of 2026 in the form of stock options in lieu of cash. On June 30th, 2026, an aggregate of 94,500 stock options was granted to directors in lieu of their director fees for the second financial quarter of 2026. All such stock options will be exercisable at a price of C$0.185 for a period of three years from the date of grant and vested immediately upon grant. In the event a director intends to exercise such stock options, such director shall be solely responsible for paying the entirety of the exercise price.

About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and critical energy in Europe and abroad.

Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
VP Corporate Development & Investor Relations
Aurania Resources Ltd.
(416) 367-3200
[email protected]

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Release – Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Posted on by [email protected]

PONTE VEDRA, Fla., June 30, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (the “Company”), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 960,000 shares of its common stock (or pre-funded warrants in lieu thereof), series C-1 warrants to purchase up to an aggregate of 960,000 shares of common stock and series C-2 warrants to purchase up to an aggregate of 960,000 shares of common stock, at a combined purchase price of $3.125 per share (or pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The series C-1 warrants will have an exercise price of $3.00 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the series C-1 warrants (the “Stockholder Approval Date”) and will expire five years after the later of (i) the Stockholder Approval Date and (ii) the effective date of a resale registration statement registering for resale all of the shares of common stock underlying the series C-1 warrants. The series C-2 warrants will have an exercise price of $3.00 per share, will be exercisable immediately upon issuance, and will expire twenty-four months after the effective date of a resale registration statement registering for resale all of the shares of common stock and the shares of common stock underlying the series C-2 warrants.

The aggregate gross proceeds to the Company from the offering are expected to be $3 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the Company from the series C-1 warrants and the series C-2 warrants, if fully exercised on a cash basis, will be approximately $5.8 million. No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants. The offering is expected to close on or about July 1, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital purposes.

The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is being investigated as a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder, and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease, those with left ventricular assist devices, and potentially, those with Kawasaki disease (KD), an acute self-limited febrile illness that primarily affects children <5 years old, and the leading cause of acquired heart disease in developed countries.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements regarding the closing of the offering, the satisfaction of customary closing conditions related to the offering, the expected gross proceeds from the offering, the Company seeking stockholder approval, receipt of stockholder approval, the filing of one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering, the intended use of net proceeds from the offering, the potential exercise of the warrants for cash prior to their expiration and the Company’s receipt of potential proceeds therefrom, net proceeds anticipated to extend the Company’s cash runway into first quarter of 2027; and the Company’s cash runway anticipated to be extended into second half of 2027 to advance partnering opportunities for tecarfarin in Kawasaki Disease (potential rare pediatric disease designation) and CAD-1005 in CSA-AKI and HIT.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to close the offering, the ability of the Company to obtain stockholder approval, the ability of the Company to advance partnering opportunities for tecarfarin in Kawasaki Disease (potential rare pediatric disease designation) and CAD-1005 in CSA-AKI and HIT; the ability to raise sufficient capital to continue progress of its product candidates; the ability to derive the results needed for an NDA submission; and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

For more information, please contact:

Lytham Partners, LLC, Robert Blum, Managing Partner, 602-889-9700, [email protected]

Release – NN, Inc. Announces $75.0 Million Private Placement

Posted on by [email protected]

CHARLOTTE, N.C., July 01, 2026 (GLOBE NEWSWIRE) — NN, Inc. (“NN” or the “Company”) (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies with six sigma quality, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of $75.0 million before deducting placement agent fees and offering expenses. The PIPE is expected to close on or about July 2, 2026, subject to the satisfaction of customary closing conditions.

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, NN will issue an aggregate of 24,509,804 shares of common stock at a price of $3.06 per share.

The Company intends to use the net proceeds from the PIPE for working capital and general corporate purposes, which may include actions designed to optimize NN’s balance sheet.

Harold Bevis, President and CEO of NN, stated, “We are excited to bring new investors into the stock who are committed to our business plan. The capital from this offering also provides us flexibility to take actions to strengthen our balance sheet, which we believe will provide long-term benefits to our investors.”

Craig-Hallum Capital Group LLC acted as the sole placement agent for the PIPE. Cooley LLP served as counsel to NN for the PIPE and Faegre Drinker Biddle & Reath served as counsel to the placement agent.

The securities being issued and sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, NN and the investors named therein entered into a registration rights agreement pursuant to which NN has agreed to file a registration statement with the U.S. Securities and Exchange Commission (“SEC”) registering the resale of the shares of common stock.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About NN

NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and China. For more information about the Company and its products, please visit www.nninc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the timing and completion of the PIPE, the use of the net proceeds from the PIPE, including any potential actions designed to optimize the Company’s balance sheet and any potential long-term benefits to our investors of such actions, and other statements that are not historical facts. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project,” “achieve,” “growth,” “enable,” “improve,” or the negative of these terms, and similar words, phrases or expressions that convey uncertainty of future events or outcomes. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such statements. Such factors include, among others, matters related to the completion of the PIPE and related transactions, including the need to satisfy the closing conditions therefor. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the SEC. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.

Investor Relations:
Joseph Caminiti
[email protected]
312-445-2870 

Release – Snail Announces Reverse Stock Split to Support Effort to Regain Compliance with Nasdaq’s Minimum Bid Price

Posted on by [email protected]

July 1, 2026 at 8:30 AM EDT

CULVER CITY, Calif., July 01, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced that it will effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of its Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”) and Class B Common Stock, par value $0.0001 per share (the “Class B Common Stock” and together with the Class A Common Stock, the “Common Stock”). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time on July 2, 2026 (the “Effective Time”). The Company’s Class A Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “SNAL” and will begin trading on a split-adjusted basis when the Nasdaq opens on July 6, 2026. The new CUSIP number for the Class A Common Stock following the Reverse Stock Split will be 83301J308.

On June 2, 2026, a written consent was delivered to the Company’s Board of Directors from the holders of 95% of the voting power of the Company’s issued and outstanding Common Stock (the “Majority Stockholders”), pursuant to which the Majority Stockholders approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split with respect to the Common Stock at a ratio of 1-for-2 to 1-for-10, with the ratio within such range to be determined at the discretion of the Board of Directors. The Company’s Board of Directors subsequently approved the final ratio for the Reverse Stock Split of 1-for-5.

The Reverse Stock Split will proportionally reduce the number of outstanding shares of Common Stock from approximately 15,468,890 shares of Class A Common Stock and 28,748,580 shares of Class B Common Stock to approximately 3,093,778 shares of Class A Common Stock and 5,749,716 shares of Class B Common Stock. The ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. Proportional adjustments will be made to the number of shares of Common Stock issuable upon exercise of outstanding warrants or options, or the conversion of outstanding convertible notes, as well as to the applicable exercise or conversion price. There will be no change to the total number of authorized shares of Common Stock as set forth in the Certificate of Incorporation. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the Reverse Stock Split to their broker. All stockholders of record may direct questions to the Company’s transfer agent, Equiniti Trust Company, LLC at 800-468-9716.

The Reverse Stock Split is intended to support the Company’s effort to regain compliance with the minimum bid price requirement for maintaining the listing of its Class A Common Stock on the Nasdaq Capital Market, and to make the bid price more attractive to a broader group of institutional and retail investors. The Nasdaq Capital Market requires, among other things, that a listed company’s common stock maintain a minimum bid price of at least $1.00 per share.

Any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) shall be entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the reverse split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the Nasdaq for the ten days preceding the Effective Time.

About Snail, Inc.

Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding the Reverse Stock Split allowing the Company to regain compliance with Nasdaq’s minimum bid price requirement, enabling the Company to attract a broader universe of investors; and assumptions underlying any of the foregoing.

Further information on risks, uncertainties and other factors that could affect Snail’s financial results and business include Snail’s ability to strengthen its gaming portfolio’s visibility; Snail’s ability to expand and grow its franchise and increase its revenue; Snail’s ability to retain its key employees or maintain its Nasdaq listing; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail, and Snail does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact

John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

Fed Chair Warsh’s Inflation Hard Line Puts Rate-Sensitive Investors on Notice

Posted on by [email protected]

There was no ambiguity in Sintra, Portugal on Wednesday. Speaking at the European Central Bank’s annual forum on central banking, Federal Reserve Chair Kevin Warsh delivered a clear message to anyone hoping the Fed had quietly accepted a new normal: it has not. “If there were people who thought that this central bank was going to be comfortable with an inflation objective above 2%,” Warsh said, “I guess they’d be disappointed. We’re going to deliver price stability in the US.”

The comments came two weeks after Warsh’s first press conference as Fed chair, where he struck a markedly more hawkish tone than markets anticipated. Rates remain at 3.50% to 3.75%, but the Fed’s own projections now show officials expect headline inflation to reach 3.6% this year, up sharply from an earlier estimate of 2.7%. Core PCE, the Fed’s preferred inflation gauge, rose to 3.4% in May, its highest reading since October 2023.

Warsh Is Deliberately Withholding Forward Guidance

One of the more consequential shifts under Warsh is what he is choosing not to say. Traditional Fed communication has relied on forward guidance, the practice of telegraphing the likely direction of rates in advance. Warsh has signaled he wants to curtail that approach, and Wednesday’s appearance was consistent: asked about the July 28-29 FOMC meeting, he offered almost nothing beyond promising a “good debate” behind closed doors.

For markets conditioned to reading Fed signals, the absence of guidance is itself a message. Investors can no longer price in a clear rate path, which introduces uncertainty that has historically weighed on higher-volatility, higher-risk assets.

A Complicated Inflation Picture

The path to 2% runs through several crosscurrents. Oil prices fell after President Trump announced a tentative deal with Iran, but negotiations have stalled and both sides have resumed strikes, keeping energy price volatility alive. Meanwhile, AI-driven demand appears to be pushing core prices higher even as supply-side productivity gains remain a future promise rather than a current reality. When asked whether AI is ultimately inflationary, Warsh declined to draw a conclusion, noting only that the Fed will make that determination and act accordingly.

Warsh also pushed back on any suggestion that political pressure would influence policy. “We’ve been an independent central bank for a very long time,” he said. “We’re going to be an independent central bank at this moment.”

What This Means for Small and Microcap Investors

This matters more for small and microcap investors than for almost any other market segment. Companies under $2 billion in market cap carry a disproportionate share of floating rate debt and depend more heavily on external financing to fund growth. When the rate path tilts toward hikes rather than cuts, the cost of that capital rises quickly, and smaller balance sheets feel it first.

The Russell 2000’s record-setting first half of 2026 was built partly on expectations of rate relief that are now being recalibrated. With the July 29 decision approaching and core inflation running above 3%, investors in smaller companies should pay close attention to balance sheet composition. Companies with manageable debt loads and strong cash generation are best positioned to navigate a higher-for-longer environment. Warsh has made his priorities clear. The question now is how quickly inflation answers back.

Conduent (CNDT) – Completes Transportation Exit

Posted on by [email protected]


Wednesday, July 01, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Tolling divestiture completes Transportation exit. Conduent announced the sale of its Tolling business to Quarterhill for $70 million, completing its previously announced exit from the Transportation segment and advancing management’s portfolio simplification strategy. The transaction is expected to close during the fourth quarter of 2026, subject to satisfaction or waiver of customary closing conditions.

Deal terms limit Conduent’s residual risk. Quarterhill will assume substantially all liabilities associated with the business, including surety bond obligations, while Conduent will retain a 7% equity stake in Quarterhill, providing potential upside participation.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Unicycive Therapeutics (UNCY) – Delay in Manufacturing Inspection Leads To Complete Response Letter (CRL)

Posted on by [email protected]


Wednesday, July 01, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We Now Expect Product Approval Around YE2026. Unicycive announced it has received a CRL (Complete Response Letter) stating that the NDA for OLC (oxylanthanum carbonate), its phosphate binder for patients on dialysis, has not been approved. The reason stated is that the FDA has not conducted its required inspection of the third-party manufacturing vendor. This step is expected to be completed during the summer, allowing for an NDA resubmission and approval near YE2026.

All Other Steps In The NDA Review Appear To Be Complete. The FDA inspection appears to have been the only remaining step for OLC approval. After a meeting with the FDA, steps to resolve manufacturing issues with the third-party vendor were identified, addressed, and the plant readied for inspection. The review of clinical efficacy and safety data was completed in 2025, with no new issues raised. Product labeling and packaging discussions have been ongoing, typically the last step before approval.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Private Payrolls Miss Expectations in June as Hiring Slows. Thursday’s Report Will Tell the Full Story

Posted on by [email protected]

The US labor market showed signs of cooling Wednesday morning, and the timing could not be more consequential. Private employers added just 98,000 jobs in June according to ADP’s monthly payroll report, falling well short of the 120,000 economists had anticipated. The miss comes one day before the government’s official employment situation report, which is expected to show a gain of approximately 115,000 positions and is being released Thursday rather than Friday due to the July 4 holiday market closure.

After months of surprisingly strong job gains that helped keep the Federal Reserve locked in a hawkish posture, the June ADP number introduces a new variable into the rate conversation at precisely the moment investors needed clarity most.

What the Data Actually Shows

The 98,000 figure represents a meaningful deceleration from May’s revised 122,000 and an even sharper slowdown from the blowout 172,000 gain reported in the government’s May payroll data. ADP’s chief economist described the report as reflecting a labor market caught between two forces: workers are taking longer to find new positions, while certain industries are simultaneously running into labor supply constraints. The net effect is a slowdown in job creation that is neither a collapse nor a continuation of the strength that characterized the spring.

Other labor market indicators released this week paint a slightly more constructive picture. Layoff announcements fell in June, and job openings for May came in stronger than economists had predicted at 7.6 million. But hiring activity itself remained weak, reinforcing a pattern the Federal Reserve’s Beige Book described last month as a “low-hire, low-fire environment” in which companies are holding headcount steady rather than expanding.

Why Thursday Matters More

The ADP report is a useful directional signal, but the government’s nonfarm payrolls report is the data point the Fed actually uses in its policy deliberations. Thursday’s number will land less than two weeks after Fed Chair Kevin Warsh’s first FOMC meeting, where the committee dropped its easing bias and signaled through its dot plot that nine of 18 officials expect at least one rate hike before year-end.

A strong Thursday print would reinforce that hawkish posture and keep rate hike probabilities elevated. A miss particularly one that aligns with ADP’s softening signal — would complicate the committee’s case for tightening and could mark the first meaningful crack in the “higher-for-longer” narrative that has dominated rate expectations since March.

The Small Cap Implications

For companies in the sub-$2 billion market cap space, the difference between those two outcomes is material. Small and microcap companies carry disproportionately more variable-rate debt than their large cap counterparts, making them acutely sensitive to shifts in rate expectations. A labor market that is genuinely cooling gives the Fed room to hold rather than hike, which would be a direct and immediate benefit to smaller balance sheets that have been absorbing elevated borrowing costs all year.

At the same time, a slowing labor market carries its own risk for consumer-facing small caps. Fewer jobs means less consumer spending power, and the companies most exposed to discretionary spending: restaurants, specialty retail, travel, and leisure feel that pressure faster than most. The staffing and employment services sector, where several smaller publicly traded companies operate, is also a direct read on hiring trends.

Wednesday’s ADP report is a warning flare, not a verdict. Thursday morning’s number is the one that will actually move the Fed’s thinking, the bond market, and the cost of capital for every small company in America.

Why Small-Cap Companies Have Become the Most Coveted Acquisition Targets of 2026

Posted on by [email protected]

The deal winter is over. After years of stalled negotiations and a near-frozen M&A market, 2026 has arrived with a thaw that is reshaping the opportunity landscape for investors at every level. U.S. merger and acquisition transactions over $100 million are up 25% by volume and 43% by value compared to the same period last year, and the companies drawing the most aggressive attention are not the household names. They are the smaller, leaner innovators that large strategics and private equity firms have been quietly circling.

The catalyst is a convergence of factors that rarely align at once. Nearly $440 billion in private equity dry powder is specifically earmarked for smaller enterprises. Stabilizing interest rates following years of Fed tightening have narrowed the valuation gap that froze so many deals. And a shift in antitrust enforcement, with the FTC under new leadership focusing scrutiny on mega-mergers rather than smaller bolt-on acquisitions, has cleared a regulatory runway that simply did not exist two years ago.

Biopharma Is Driving the Biggest Wave

Nowhere is the acquisition appetite more pronounced than in life sciences. IQVIA forecasts aggregate biopharma M&A deal value of $140 billion to $160 billion for full-year 2026, with upside potential of an additional $20 to $30 billion. Oncology is the primary target area, accounting for roughly 39% of total transaction volume. Large pharmaceutical companies facing patent cliffs on blockbuster drugs are finding it more capital-efficient to acquire late-stage small-cap biotechs than to fund the same pipeline development in-house.

Small-cap developers in oncology, rare disease, and high-growth therapeutic categories like GLP-1 drugs, where the market opportunity is projected to reach $100 billion by 2030, are drawing the most serious acquirer interest. Companies like Cardiff Oncology and MAIA Biotechnology are among the smaller-cap names building programs in therapeutic areas where large-cap acquirers are actively hunting for pipeline replenishment.

How Deal Structures Have Evolved

It is not just volume that has shifted. The mechanics of how deals get done have evolved as well. Today’s acquirers are structuring transactions around free cash flow multiples and sustainable margins, rather than the growth-at-any-cost narratives that defined the SPAC era. Contingent value rights (CVRs) are increasingly common, allowing buyers and sellers to share risk on clinical or commercial milestones, which makes smaller biotech deals executable even under significant uncertainty.

This shift favors companies with differentiated science and disciplined financials over those with only a compelling story. For acquirers, the logic is clear: buying validated late-stage assets is cheaper than building them internally, particularly in a higher-rate environment.

What This Means for Small and Microcap Investors

For investors focused on small and microcap companies, this is among the most favorable M&A backdrops in recent memory. Acquisition premiums in small-cap biotech and specialty pharma deals have historically ranged from 50% to over 100% above pre-announcement prices. The profiles that attract strategic buyers, differentiated pipelines, clean balance sheets, and validated mechanisms of action, are concentrated precisely in the sub-$2 billion market cap space where most individual investors are underexposed.

The opportunity is not in chasing deal rumors. It is in understanding the strategic logic driving large-cap acquirers: they need what smaller companies have built, and in 2026, they are increasingly willing to pay for it.

Two RV Component Giants Are Merging to Build an $8.1 Billion Outdoor Powerhouse

Posted on by [email protected]

Two of the most important names in the recreational vehicle and outdoor recreation supply chain are joining forces. Patrick Industries (Nasdaq: PATK) and LCI Industries (NYSE: LCII) the latter known commercially as Lippert announced Tuesday they have entered into a definitive agreement to combine in an all-stock merger, creating a premier component solutions provider serving the outdoor enthusiast, housing, and transportation markets. The boards of both companies unanimously approved the transaction.

Under the terms, LCI shareholders will receive 1.2440 shares of Patrick common stock for each LCI share they own. When the deal closes, Patrick shareholders will own approximately 52% of the combined company and LCI shareholders approximately 48% — a near-even split that reflects the comparable scale of the two businesses.

The Scale of the Combined Company

The merger creates a genuine industry heavyweight. On a pro forma basis, the combined company would have generated approximately $8.1 billion in revenue over the trailing twelve months as of March 2026, with adjusted EBITDA of $1.0 billion and free cash flow of $508 million, both inclusive of expected synergies. Those are substantial figures in the component manufacturing space and give the combined entity meaningful scale across its end markets.

The financial case rests heavily on cost synergies. Management expects the transaction to deliver more than $150 million in run-rate cost savings within three years of closing. The company describes those synergies as identified and actionable, arising primarily from procurement efficiencies, selling, general and administrative streamlining, shared engineering best practices, and improved supply chain management, the kind of operational overlap that two companies serving similar customers and end markets can realistically capture.

Why These Two Companies Fit Together

Both Patrick and LCI are component solutions providers with deep, longstanding relationships across the recreational vehicle, marine, manufactured housing, and broader outdoor recreation industries. They supply the parts and systems that go into RVs, boats, manufactured homes, and other products built for life outdoors. Their portfolios are complementary rather than overlapping in a way that would raise significant antitrust concern, and both maintain established customer partnerships across North America and Europe.

The combined leadership structure reflects the partnership nature of the deal. Patrick’s Andy Nemeth will serve as CEO of the combined company, while Todd Cleveland will become Chair and LCI’s Johnny Sirpilla will serve as Vice Chair of the board. That distribution of senior roles across both legacy organizations signals an intent to integrate the two cultures rather than have one absorb the other.

The Cyclical Context

The timing of this combination is worth understanding. The recreational vehicle and outdoor recreation industries are highly cyclical, and they have navigated a challenging stretch as elevated interest rates pressured big-ticket discretionary purchases like RVs and boats throughout 2025 and into 2026. By combining, Patrick and LCI gain the scale, cost structure, and balance sheet flexibility to weather cyclical downturns more effectively and to invest through the cycle rather than retrench during it.

For investors tracking the small and mid cap industrial and consumer discretionary space, this merger carries a familiar signal. In sectors facing cyclical pressure and margin compression, scale becomes a defensive advantage. Companies with complementary products and overlapping cost structures are increasingly choosing to combine rather than compete, pooling resources to improve procurement leverage, operational efficiency, and resilience. The outdoor recreation supply chain just produced one of the clearest examples of that logic in 2026 at $8.1 billion in combined revenue, the resulting company will be a dominant force in its markets when conditions in the RV and outdoor industries eventually turn back up.

Star Equity Holdings, Inc. (STRR) – A First Step

Posted on by [email protected]


Tuesday, June 30, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Russell Microcap Index.  Star Equity Holdings’ common stock has been added to the Russell Microcap® Index following the 2026 Russell indexes reconstitution, which became effective after the U.S. market close on June 26, 2026. We view the inclusion of Star in the Microcap Index as the first step in management’s goal to be added to the Russell 2000 Index.

Russell Microcap Index. The reconstitution of the Russell U.S. Indexes captures the 4,000 largest U.S. stocks as of April 30, 2026, ranked by total market capitalization. The Russell Microcap® Index measures the performance of the microcap segment of the U.S. equity market and is used by institutional investors and investment managers as a benchmark for microcap equities.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – Expanding Data Center Business

Posted on by [email protected]


Tuesday, June 30, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Awards. NN has secured a significant amount of additional 2026 immediate-supply awards for liquid cooling products that go into NVIDIA AI data center racks. The new awards are additive to prior communicated awards and greatly increase the size of NN’s liquid cooling product portfolio for AI data center racks. NN’s combined Data Center and Electric Grid business is already its 2nd-largest business, with a goal to grow it into the Company’s largest business by sales. The Data Center & Electric Grid end markets are the top targeted growth markets for the Company.

Successful Launch. In 1Q26, NN announced the launch of a custom-designed stainless-steel product line for the liquid-cooled data center market. Since then, the Company has secured multiple AI data center awards, invested in an initial complement of 17 next-generation, high-speed, high-precision CNC machines at its Wuxi, China, plant, and begun production.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Russell Reconstitution 2026 Takes Effect: 237 New Names Join the Small Cap Index

Posted on by [email protected]

The Russell US Indexes reconstitution that we previewed earlier this month officially took effect at the close of trading Friday, and US markets opened this morning, Monday June 29, with the newly recalibrated indexes in operation. The timing is notable. Just last week we wrote about the market rotation finally broadening beyond a handful of mega cap technology names and into small caps — and this reconstitution is the structural machinery that formalizes exactly that shift, recalibrating which companies sit in which index after a year of dramatic movement across the market cap spectrum.

After a query period, a lock-down phase, and one of the highest-volume trading sessions of the year on Friday, the 2026 reconstitution is now complete — and the changes offer a revealing snapshot of how the US equity market has evolved over the past twelve months.

A Market That Grew 29% in a Year

The headline figure is the scale of the market’s expansion. The total market capitalization of the Russell 3000 — the broad index designed to capture roughly 98% of the investable US equity market — rose 29% from $58.4 trillion at last year’s reconstitution to $75.6 trillion as of the April 30 rank day. That growth rippled through every layer of the index family. The market capitalization breakpoint separating large-cap companies in the Russell 1000 from small-cap companies in the Russell 2000 increased 24% to $5.7 billion. At the lower boundary, the smallest company in the Russell 2000 now carries a market cap of approximately $146 million, up nearly 23% from a year ago.

A Historic Shakeup at the Top

One of the most striking changes occurred among the largest companies in the index. For more than a decade, Apple and Microsoft traded places as the two largest US companies. This year broke that pattern. Driven by the artificial intelligence boom, Nvidia rose from third place in 2025 to become the largest company in both the Russell 3000 and Russell 1000, while Alphabet climbed from fifth to second. Apple and Microsoft slipped to third and fourth. It is the clearest index-level evidence yet of how completely AI has reshaped market leadership.

The Small Cap Story Beneath the Surface

For ChannelChek’s audience, the more relevant action is happening lower down the market cap spectrum. A total of 237 companies were added to the Russell 2000 this cycle, with additions concentrated most heavily in health care, followed by technology, industrials, and consumer discretionary. That cohort includes 82 companies migrating up from the Russell Microcap Index, 37 moving down from the Russell 1000, and 101 newly eligible entrants joining from outside the Russell universe. Seventeen IPOs were added directly to the small cap index, led by eight health care names.

The reconstitution also revealed the strength of the recent small cap surge through its banding mechanism. A remarkable 97 existing Russell 2000 constituents ranked above the large cap breakpoint based on market cap but remained in the small cap index because they fell within the retention band — a buffer designed to reduce unnecessary turnover. That is an unusually high number, and it reflects just how many small cap companies have appreciated toward large cap territory over the past year.

Why the Semi-Annual Shift Matters Going Forward

This reconstitution carries lasting structural significance because 2026 marks the first time since 1989 that FTSE Russell has moved to a semi-annual schedule. A second reconstitution will now occur in December, and the implications are real. With roughly $12 trillion in assets benchmarked to Russell indexes, the addition of a December rebalance means that companies growing rapidly into or shrinking out of an index will be repositioned far faster than the prior annual cadence allowed.

For active small cap managers, that change raises the stakes around benchmark awareness and risk management. Stocks that appreciate quickly can now be migrated to a new index in months rather than waiting a full year, compressing the window in which fundamental changes get reflected in index composition. For investors, the practical takeaway is that index inclusion remains a powerful driver of passive fund flows and liquidity — but inclusion is not the same as fundamental validation. A company can join an index and still carry execution, dilution, or earnings risk. The reconstitution list is best understood as a map of where benchmark-driven attention may flow, not a substitute for due diligence.

The rebalanced indexes are live. The market they represent looks materially different than it did a year ago — larger at the top, broader beneath the surface, and now recalibrated twice as often as it was for the prior 37 years.